Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Cost Saving Opportunities in NSCLC Therapy by Optimized Diagnostics.
Nenadić I
,
Staber J
,
Dreier S
,
Simons G
,
Schildgen V
,
Brockmann M
,
Schildgen O
.
Abstract
With an incidence of 68 new cases per 100,000 people per year, an estimated total number of up to 350,000 new non-small-cell lung cancer (NSCLC) cases are diagnosed each year in the European Union. Up to 10% of NSCLC patients are eligible for therapy with novel ALK (anaplastic lymphoma kinase) inhibitors, as they have been diagnosed with a mutation in the gene coding for ALK. The ALK inhibitor therapy costs add up to approx. 9,000 € per patient per month, with treatment durations of up to one year. Recent studies have shown that up to 10% of ALK cases are misdiagnosed by nearly 40% of pathologic investigations. The current state-of-the-art ALK diagnostic procedure comprises a Fluorescent in situ Hybridization (FISH) assay accompanied by ALK inhibitor therapy (Crizotinib). The therapy success ranges between a full therapy failure and the complete remission of the tumor (i.e., healing), but the biomedical and systemic reasons for this range remain unknown so far. It appears that the variety of different ALK mutations and variants contributes to the discrepancy in therapy results. Although the major known fusion partner for ALK in NSCLC is the Echinoderm microtubule-associated protein-like 4 (EML4), of which a minimum of 15 variants have been described, an additional 20 further ALK fusion variants with other genes are known, of which three have already been found in NSCLC. We hypothesize that the wide variety of known (and unknown) ALK mutations is associated with a variable therapy success, thus rendering current companion diagnostic procedures (FISH) and therapy (Crizotinib) only partly applicable in ALK-related NSCLC treatment. In cell culture, differing sensitivity to Crizotinib has been shown for some fusion variants, but it is as yet unknown which of them are really biologically active in cancer patients, and how the respective variants affect the response to Crizotinib treatment. Moreover, it has been demonstrated that translocated ALK genes can also be observed in healthy tissues and are not compulsorily associated with tumors. Therefore, it is important to keep in mind that even for the known variants of ALK fusion genes, the biological function is not known for all variants, and that no information is available on the homogeneity of ALK fusion variants within a single tumor. These facts, in concert with data for ALK mutation prevalence and therapy outcomes of a German cohort of NSCLC patients, support the hypothesis that, by using novel companion diagnostic tools in combination with therapy outcome predictions, massive cost savings could be possible in European Health Care systems without a loss of patient care.
Barlesi,
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).
2016, Pubmed
Barlesi,
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).
2016,
Pubmed
Bogojeska,
Hierarchical Bayes model for predicting effectiveness of HIV combination therapies.
2012,
Pubmed
Bozek,
An expanded model of HIV cell entry phenotype based on multi-parameter single-cell data.
2012,
Pubmed
Guérin,
Treatment, overall survival, and costs in patients with ALK-positive non-small-cell lung cancer after crizotinib monotherapy.
2015,
Pubmed
Hammerschmidt,
Lung cancer: current diagnosis and treatment.
2009,
Pubmed
Jürgens,
Combined point mutation in KRAS or EGFR genes and EML4-ALK translocation in lung cancer patients.
2014,
Pubmed
Jürgens,
The (Con-) Fusion in ALK Diagnostics: When Food and Drug Administration-Approved Algorithms Fail.
2016,
Pubmed
Kasapoglu,
Prognostic factors affecting survival in non-small cell lung carcinoma patients with malignant pleural effusions.
2016,
Pubmed
Kelly,
Cost effectiveness of crizotinib for anaplastic lymphoma kinase-positive, non-small-cell lung cancer: who is going to blink at the cost?
2014,
Pubmed
Kwak,
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
2010,
Pubmed
Lengauer,
Bioinformatics-assisted anti-HIV therapy.
2006,
Pubmed
Lengauer,
Bioinformatics prediction of HIV coreceptor usage.
2007,
Pubmed
Li,
Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays.
2014,
Pubmed
,
Echinobase
Li,
Clinical features and mutation status of EGFR, KRAS, BRAF, EML4-ALK and ROS1 between surgical resection samples and non surgical resection samples in lung cancer.
2015,
Pubmed
Liu,
Detection of EML4-ALK in lung adenocarcinoma using pleural effusion with FISH, IHC, and RT-PCR methods.
2015,
Pubmed
Loens,
Performance of different mono- and multiplex nucleic acid amplification tests on a multipathogen external quality assessment panel.
2012,
Pubmed
Lozano,
Variations in molecular profile in NSCLC can be analyzed using cytological samples: development of EGFR resistance mutations and coexistence of ALK-EML4 translocation in an EGFR-sensitive patient.
2015,
Pubmed
Mak,
Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases.
2015,
Pubmed
Mano,
The EML4-ALK oncogene: targeting an essential growth driver in human cancer.
2015,
Pubmed
Maus,
Identification of Novel Variant of EML4-ALK Fusion Gene in NSCLC: Potential Benefits of the RT-PCR Method.
2012,
Pubmed
,
Echinobase
Nenadić,
Cost Saving Opportunities in NSCLC Therapy by Optimized Diagnostics.
2017,
Pubmed
Olsen,
Companion diagnostics for targeted cancer drugs - clinical and regulatory aspects.
2014,
Pubmed
Ou,
Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer.
2010,
Pubmed
Pan,
ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
2014,
Pubmed
Pfeifer,
Improving HIV coreceptor usage prediction in the clinic using hints from next-generation sequencing data.
2012,
Pubmed
Popper,
Molecular testing in lung cancer in the era of precision medicine.
2014,
Pubmed
,
Echinobase
Reijans,
RespiFinder: a new multiparameter test to differentially identify fifteen respiratory viruses.
2008,
Pubmed
Schildgen,
Epidemiology of driver mutations in lung cancer in a German tertiary hospital in patients with testing indication.
2016,
Pubmed
Schildgen,
Routine molecular profiling of patients with NSCLC.
2016,
Pubmed
Shaw,
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
2011,
Pubmed
Shaw,
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
2009,
Pubmed
Thielen,
Geno2pheno[454]: a Web server for the prediction of HIV-1 coreceptor usage from next-generation sequencing data.
2012,
Pubmed
To,
Detection of ALK rearrangement by immunohistochemistry in lung adenocarcinoma and the identification of a novel EML4-ALK variant.
2013,
Pubmed
,
Echinobase
V Laffert,
Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): results of a multi-centre ALK-testing.
2013,
Pubmed
von Laffert,
Multicenter ALK testing in non-small-cell lung cancer: results of a round robin test.
2014,
Pubmed
Warth,
[Novel morphological and molecular aspects of lung cancer].
2013,
Pubmed
Wolf,
[Personalized, targeted treatment of non-small cell lung cancer].
2011,
Pubmed
Yousem,
Role of molecular studies in the diagnosis of lung adenocarcinoma.
2012,
Pubmed
Zhao,
Lung adenocarcinoma harboring concomitant EGFR mutation and EML4-ALK fusion that benefits from three kinds of tyrosine kinase inhibitors: a case report and literature review.
2015,
Pubmed